METTL3 and acute myeloid leukemia: Additionally, we observed that HSCT prolonged the survival of METTL3‐positive AML patients (median OS not reached vs. 12 months, p = 0.0137; median EFS 15.7 vs7.2 months, p = 0.0137) (Figure 3A).